Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia

Leukemia Research

Volumn 26, Issue 2, 2002, Pages 143-154

  Tsimberidou, Apostolia Maria ^a,c   Paterakis, George ^b   Androutsos, George ^b   Anagnostopoulos, Nikolaos ^a   Galanopoulos, Athanasios ^a   Kalmantis, Themistoklis ^a   Meletis, John ^a   Rombos, Yiannis ^a   Sagriotis, Alexandros ^a   Symeonidis, Argyrios ^a   Tiniakou, Maria ^a   Zoumbos, Nikolaos ^a   Yataganas, Xenophon ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b G GENNIMATAS GENERAL HOSPITAL   (Greece)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Lung resistance protein; Multidrug resistance protein; P glycoprotein; Primary acute myelogenous leukemia

Indexed keywords

CALCEIN; CD7 ANTIGEN; CYTARABINE; DAUNORUBICIN; GENISTEIN; GLYCOPROTEIN P; IDARUBICIN; LUNG RESISTANCE PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY JSB1; MONOCLONAL ANTIBODY LRP56; MONOCLONAL ANTIBODY MRPM6; MULTIDRUG RESISTANCE PROTEIN; PROBENECID; RHODAMINE 123; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER SURVIVAL; CONTROLLED STUDY; CYTOGENETICS; FEMALE; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOPHENOTYPING; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT FAILURE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CALCIUM CHANNEL BLOCKERS; CARBOCYANINES; COMBINED MODALITY THERAPY; CYTARABINE; DAUNORUBICIN; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; FLUORESCEINS; FLUORESCENT DYES; GENISTEIN; HUMANS; IDARUBICIN; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PROBENECID; PROGNOSIS; PROSPECTIVE STUDIES; RHODAMINE 123; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED; VAULT RIBONUCLEOPROTEIN PARTICLES; VERAPAMIL;

EID: 0036137810     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(01)00106-0     Document Type: Article

References (74)

1. Transplantation in first remission of acute myeloid leukemia
2. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10)
3. Varying intensity of postremission therapy in acute myeloid leukemia
4. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission
5. Acute myeloblastic leukaemia in the elderly: Biology, prognostic factors and treatment
6. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
7. Expression of a multidrug-resistance gene in human tumors and tissues
8. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
9. Expression of the human major vault protein LRP in acute myeloid leukemia
10. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance
11. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia
12. Clinical relevance of P-glycoprotein expression in haematological malignancies
13. The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia
14. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group study
15. Measuring multidrug resistance expression in human malignancies: Elaboration of consensus recommendations
16. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative group
17. Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia
18. Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance
19. P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells
20. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia
21. Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry
22. Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein
23. Fluorescent cellular indicators are extruded by the multidrug resistance protein
24. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients
25. 2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux
26. Lack of reversal of daunorubicin resistance in HL60/AR cells by cyclosporin A
27. ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): No inhibition by intracellular glutathione depletion
28. BIBW22 BS, potent multidrug resistance-reversing agent, binds directly to P-glycoprotein and accumulates in drug-resistant cells
29. Quality control of multidrug resistance assays in adult acute leukemia: Correlation between assays for P-glycoprotein expression and activity
30. Analysis of the interactions of SDZ PSC 833 ([3′-keto-Bmt1]-Val2]-Cyclosporine), a multidrug resistance modulator, with P-glycoprotein
31. SDZ PSC 833, a non-immunosuppressive cyclosporin analog, is a very potent multidrug-resistance modifier
32. Statistical principles for clinical trials: ICH harmonised tripartite guideline
33. Non-parametric estimation from incomplete observations
34. Asymptomatically efficient rank-invariant test procedures
35. Regression models and life tables
36. P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy
37. Development of drug resistance is reduced with idarubicin relative to other anthracyclines
38. Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metabolites in human MDR1 transfected NIH-3T3 cells
39. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Group study
40. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis
41. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study
42. Multidrug resistance gene expression in acute myeloid leukemia: Major prognosis significance for in vivo drug resistance to induction treatment
43. MDR1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukemia
44. P-glycoprotein (P-170) and CD34 expression in adult acute myeloid leukemia (AML)
45. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia
46. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome
47. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia
48. Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia
49. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia
50. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: Biological and clinical implications
51. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia
52. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival
53. Multicentric evaluation of the MDR phenotype in leukemia
54. Assays for the analysis of P-glycoprotein in acute myeloid leukemia and CD34 subsets of AML blasts
55. Acute myeloid leukemia
56. Surface marker expression in acute myeloid leukemia at first relapse
57. CD7 augments T cell proliferation via the interleukin-2 autocrine pathway
58. Analysis of CD7 expression in acute myelogenous leukemia: Martingale residual plots combined with 'optimal' cutpoint analysis reveals absence of prognostic significance
59. The value of detecting surface and cytoplasmic antigens in acute myeloid leukemia
60. Clinical importance of CD7 expression in acute myelocytic leukemia
61. Immunophenotype of acute myeloid leukemia: Correlation with morphological characteristics and therapy response
62. Prognostic impact of karyotype and immunologic phenotype in 125 adult patients with de novo AML
63. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar)
64. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: A randomized multicenter study
65. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: An Eastern Cooperative Oncology Group pilot study
66. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia